Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2021 | Exciting combinations under investigation in lymphoma

Stephen Ansell • 11 Dec 2021
ASH 2021
Diffuse Large B-Cell Lymphoma Hodgkin Lymphoma Lymphoma Antibodies Polatuzumab vedotin Ruxolitinib Vorinostat

Stephen Ansell, MD, PhD, Mayo Clinic, Rochester, MI, talks on novel combinations on the horizon for the treatment of lymphoma, highlighting studies assessing the addition of ruxolitinib or vorinostat to PD-1 blockade in Hodgkin lymphoma and polatuzumab vedotin plus chemotherapy in relapsed/refractory diffuse large B-cell lymphoma (DLBCL). This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.

More from Stephen Ansell

MBL: biology, classification & the possibility of early interception
Andrew Rawstron et al. • 25 Mar 2024
1:03
What’s on the horizon for Hodgkin lymphoma?
Stephen Ansell • 11 Dec 2023
0:51
Treating patients with Hodgkin lymphoma who are chemo-resistant
Stephen Ansell • 11 Dec 2023
1:21
Hodgkin lymphoma highlights from ASH 2023: nivo-AVD versus BV-AVD in patients with HL
Stephen Ansell • 11 Dec 2023

Related Videos

1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
2:28
Checkpoint inhibitors vs brentuximab vedotin as salvage therapy prior to alloSCT for HL
Jacopo Mariotti • 15 Apr 2024
1:37
Exciting CAR-T clinical trials in LBCL and FL
Gloria Iacoboni • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals